Brand Name: SB-Glim 1,2,3 & 4
Generic Name with Specification: Glimepiride USP
Strength: 1,2,3 & 4 mg
SB-Glim 1 : Each Tablet contains Glimepiride USP 1 mg.
SB-Glim 2 : Each Tablet contains Glimepiride USP 2 mg.
SB-Glim 3 : Each Tablet contains Glimepiride USP 3 mg.
SB-Glim 4 : Each Tablet contains Glimepiride USP 4 mg.
Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycemic control. Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent. Combined use of Glimepiride and insulin may increase the potential for hypoglycemia.
Dosage & Administration:
In principle, the dosage of SB-Glim (Glimepiride) is governed by the desired blood sugar level. The dosage of SB-Glim (Glimepiride) must be the lowest which is sufficient to achieve the desired metabolic control. The initial and the maintenance doses are set based on the results of regular check of glucose in blood and urine. Monitoring of glucose levels in blood and urine also serves to detect either primary or secondary failure of therapy.
Initial dose and dose titration: The usual initial dose is 1 mg once daily. If necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e., at intervals of one to two weeks, and carried out stepwise, as follows: 1mg→2mg→3mg→4mg→6mg.
Dose range in patients with well controlled diabetes: The usual dose range in patients with well controlled diabetes is 1 to 4 mg daily.
Hypoglycaemia, temporary visual impairment, nausea, vomiting diarrhoea, abdominal pain, urticaria, fall in blood pressure.
Glimepiride is not suitable for the treatment of insulin dependent (type-1) diabetes mellitus or for the treatment of diabetes with a history of ketoacidosis) nor for the treatment of diabetic precoma or coma. Glimepiride must not be used in patients hypersensitive to glimepiride & other sulphonylureas, other sulfonamides, severe hepatic dysfunction, severe impairment of renal function and dialysis patients.
Use in Pregnancy & Lactation:
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. On the basis of results from animal studies, Glimepiride should not be used during pregnancy. Patients who are planning a pregnancy should consult their physician, and it is recommended that they change over to insulin for the entire course of pregnancy and lactation.
Nursing mothers: Although it is not known whether Glimepiride is excreted in human milk, other sulfonylureas are excreted in human milk. Because the potential for hypoglycemia in nursing infants may exist, Glimepiride should be discontinued in nursing mothers. Insulin therapy should be considered in this situation.
SB-Glim 1 : Each box contains 60 tablets in blister pack.
SB-Glim 2 : Each box contains 60 tablets in blister pack.
SB-Glim 3 : Each box contains 50 tablets in blister pack.
SB-Glim 4 : Each box contains 50 tablets in blister pack.